In children presenting to the emergency department with a moderate acute asthma attack, does the addition of ipratropium bromide decrease hospital admission rate?

Phase 4

• Conditions: asthma; Respiratory - Asthma

• Registration Number: ACTRN12612000829819
• Lead Sponsor: john hunter emergency

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-08-07
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 128

Inclusion Criteria

Children aged >2 and < 16 years with a clinical diagnosis of acute moderate asthma exacrebation

Exclusion Criteria

Children with mild or severe/life threatening asthma
Children borne before 34 weeks of gestation
Children suffering from following pathologies: chronic pulmonary diseases (examples: cystic fibrosis, bronchopulmonary dysplasia), congenital heart or lung disease, recurrent pulmonary inhalations, neuromuscular disease
Immunocompromised children
Children with confirmed pneumonia
Children who have received corticosteroid within 24 hours of presentation and/or atrovent or ventolin with 3 hours of presentation
Children for whom parent/carer refused to give informed consent
Children who have had a previous episode of acute asthma requiring ICU admission/intervention, including treatment with magnesium

Study & Design

• Study Type: Interventional
• Study Design: Not specified